BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 1090648)

  • 1. Niridazole. II. A potent long-acting suppressant of cellular hypersensitivity.
    Mahmoud AA; Mandel A; Warren K; Webster LT
    J Immunol; 1975 Jan; 114(1 Pt 2):279-83. PubMed ID: 1090648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spontaneous modulation of granulomatous hypersensitivity in schistosomiasis mansoni.
    Boros DL; Pelley RP; Warren KS
    J Immunol; 1975 May; 114(5):1437-41. PubMed ID: 804513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo suppression of delayed hypersensitivity by thiabendazole and diethylcarbamazine.
    Hewlett EL; Hamid OY; Ruffier J; Mahmoud AA
    Immunopharmacology; 1981 Dec; 3(4):325-32. PubMed ID: 7327923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induced and spontaneous diabetes mellitus and suppression of cell-mediated immunologic responses. Granuloma formation, delayed dermal reactivity and allograft rejection.
    Mahmoud AA; Rodman HM; Mandel MA; Warren KS
    J Clin Invest; 1976 Feb; 57(2):362-7. PubMed ID: 130384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of cell-mediated immunity by metronidazole.
    Grove DI; Mahmound AA; Warren KS
    Int Arch Allergy Appl Immunol; 1977; 54(5):422-7. PubMed ID: 328408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression of delayed hypersensitivity in schistosome-infected patients by niridazole.
    Webster LT; Butterworth AE; Mahmoud AA; Mngola EN; Warren KS
    N Engl J Med; 1975 May; 292(22):1144-7. PubMed ID: 1124104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Niridazole, a potent long-acting suppressant of cellular hypersensitivity. III. Minimal suppression of antibody responses.
    Pelley RP; Pelley RJ; Stavitsky AB; Mahmoud AA; Warren KS
    J Immunol; 1975 Dec; 115(6):1477-82. PubMed ID: 1184961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delayed hypersensitivity granuloma formation and modulation around Schistosoma mansoni eggs in vitro. II. Regulatory T cell subsets.
    Doughty BL; Phillips SM
    J Immunol; 1982 Jan; 128(1):37-42. PubMed ID: 6976377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro delayed hypersensitivity granuloma formation: development of an antigen-coated bead model.
    Bentley AG; Phillips SM; Kaner RJ; Theodorides VJ; Linette GP; Doughty BL
    J Immunol; 1985 Jun; 134(6):4163-9. PubMed ID: 3886798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Corneal allografts induce cytotoxic T cell but not delayed hypersensitivity responses in mice.
    Peeler J; Niederkorn J; Matoba A
    Invest Ophthalmol Vis Sci; 1985 Nov; 26(11):1516-23. PubMed ID: 2414248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delayed hypersensitivity granuloma formation around Schistosoma mansoni eggs in vitro. III. Granuloma formation and modulation in human Schistosomiasis mansoni.
    Doughty BL; Ottesen EA; Nash TE; Phillips SM
    J Immunol; 1984 Aug; 133(2):993-7. PubMed ID: 6234365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo suppression by cholera toxin of cell-mediated and foreign body inflammatory responses.
    Warren KS; Mahmoud AA; Boros DL; Rall TW; Mandel MA; Carpenter CC
    J Immunol; 1974 Mar; 112(3):996-1007. PubMed ID: 4359787
    [No Abstract]   [Full Text] [Related]  

  • 13. Delayed hypersensitivity granuloma formation around Schistosoma mansoni eggs in vitro. I. Definition of the model.
    Doughty BL; Phillips SM
    J Immunol; 1982 Jan; 128(1):30-6. PubMed ID: 6976375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant IL-10 and IL-10/Fc treatment down-regulate egg antigen-specific delayed hypersensitivity reactions and egg granuloma formation in schistosomiasis.
    Flores-Villanueva PO; Zheng XX; Strom TB; Stadecker MJ
    J Immunol; 1996 May; 156(9):3315-20. PubMed ID: 8617955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Schistosoma mansoni: impairment of the cell-mediated immune response in mice.
    Araujo FG; Coelho PM; Pereira LH; Pellegrino J
    Clin Exp Immunol; 1977 May; 28(2):289-91. PubMed ID: 326446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of allograft rejection in New Zealand mice. II. Role of a serum factor.
    Gelfand MC; Parker LM; Steinberg AD
    J Immunol; 1974 Jul; 113(1):1-8. PubMed ID: 4598887
    [No Abstract]   [Full Text] [Related]  

  • 17. T cell subsets in the immune rejection of murine heterotopic corneal allografts.
    Matoba AY; Peeler JS; Niederkorn JY
    Invest Ophthalmol Vis Sci; 1986 Aug; 27(8):1244-54. PubMed ID: 2942516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FTY720 in combination with cyclosporine--an analysis of skin allograft survival and renal function.
    Silva FR; Silva LB; Cury PM; Burdmann EA; Bueno V
    Int Immunopharmacol; 2006 Dec; 6(13-14):1911-8. PubMed ID: 17161344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific migration of antigen-sensitive lymphocytes form the spleen to the site of allograft.
    Olszewski WL; Stepkowski S
    Arch Immunol Ther Exp (Warsz); 1981; 29(4):529-34. PubMed ID: 7036937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycopeptides in soluble egg antigen of Schistosoma mansoni: isolation, characterization, and elucidation of their immunochemical and immunopathological relation to the major egg glycoprotein (MEG).
    Lustigman S; Mahmoud AA; Hamburger J
    J Immunol; 1985 Mar; 134(3):1961-7. PubMed ID: 3918114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.